Basel Medical regains Nasdaq bid-price compliance

Basel Medical Group Ltd reports that Nasdaq has notified the company it has regained compliance with Nasdaq’s minimum bid price rule.

Rhea-AI Filing Summary

Basel Medical Group Ltd reports that Nasdaq has notified the company it has regained compliance with Nasdaq’s minimum bid price rule. The ordinary shares closed at $1.00 per share or greater for 10 consecutive business days from June 23, 2026 to July 7, 2026, satisfying Nasdaq Listing Rule 5550(a)(2) after a prior deficiency notice issued on January 22, 2026.

The company continues to operate a network of medical clinics in Singapore focused on orthopedic, trauma, neurosurgical and general medical services, serving corporate and individual clients across multiple locations.

Positive

• Regained Nasdaq listing compliance by meeting the minimum $1.00 bid price for 10 consecutive business days, removing an immediate risk of delisting.

Negative

• None.

Insights

Equity market structure analyst

Nasdaq bid-price compliance removes an immediate listing risk.

Basel Medical Group has restored compliance with Nasdaq’s minimum bid price requirement after its shares closed at or above $1.00 for 10 consecutive business days from June 23, 2026 to July 7, 2026. This resolves a deficiency first cited on January 22, 2026, when the stock had traded below $1.00 for 30 straight business days.

Regaining compliance reduces the near-term risk of delisting from the Nasdaq Capital Market, which can affect liquidity and investor access. Future compliance will still depend on maintaining the bid price at or above the required threshold under Listing Rule 5550(a)(2).

Key Figures

Minimum bid price threshold: $1.00 per share Non-compliance notice date: January 22, 2026 Compliance measurement window: 10 consecutive business days +2 more

5 metrics

Minimum bid price threshold $1.00 per share Required under Nasdaq Listing Rule 5550(a)(2) for continued listing

Non-compliance notice date January 22, 2026 Date Nasdaq notified BMGL of failure to maintain $1.00 minimum bid price over 30 days

Compliance measurement window 10 consecutive business days From June 23, 2026 to July 7, 2026 with closing bid at or above $1.00

Prior deficiency window 30 consecutive business days Period over which shares traded below $1.00 before Nasdaq’s January 22, 2026 notice

Media contact phone +65 6291 9188 Basel Medical Group Ltd media contact number in Singapore

Key Terms

minimum bid price rule, Listing Rule 5550(a)(2), foreign private issuer, forward-looking statements

4 terms

minimum bid price rule regulatory

"it has received notification from Nasdaq that the Company has regained compliance with the Nasdaq minimum bid price rule"

A minimum bid price rule is a stock market requirement that a listed company's share must trade above a set minimum price over a specified period to remain listed on an exchange. It matters to investors because falling below that threshold can trigger warnings, potential delisting, and reduced liquidity—similar to a student needing a passing grade to stay enrolled—making the shares harder to buy, sell, or value accurately.

Listing Rule 5550(a)(2) regulatory

"Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2)."

Listing Rule 5550(a)(2) is a Nasdaq listing standard that sets a minimum share-price requirement for securities to be listed or to remain listed on the Nasdaq Capital Market. It matters to investors because falling below that minimum can trigger delisting reviews or increased volatility, much like a safety bar on a ride — if a stock can’t meet the height requirement, it risks being removed from the exchange, which can reduce liquidity and access for buyers and sellers.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

forward-looking statements financial

"Certain statements in this announcement are forward-looking statements, which involve known and unknown risks"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

What did Basel Medical Group Ltd (BMGL) announce in this Form 6-K?

Basel Medical Group Ltd announced that Nasdaq confirmed the company has regained compliance with the Nasdaq minimum bid price rule for continued listing.

How did BMGL regain compliance with Nasdaq’s minimum bid price rule?

BMGL regained compliance after its ordinary shares had a closing bid price of $1.00 or greater for 10 consecutive business days from June 23, 2026 to July 7, 2026.

When was Basel Medical Group Ltd initially notified of non-compliance by Nasdaq?

On January 22, 2026, Nasdaq notified Basel Medical Group Ltd that its ordinary shares had traded below a $1.00 minimum bid price for 30 consecutive business days.

Which Nasdaq listing rule did BMGL return to compliance with?

Basel Medical Group Ltd returned to compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for continued listing.

What type of services does Basel Medical Group Ltd (BMGL) provide?

Basel Medical Group Ltd provides orthopedic and trauma services, sports medicine, neurosurgical treatments, executive health screening, occupational medicine, rehabilitation, mental and women’s health, and general medical services in Singapore.

Where are Basel Medical Group Ltd’s clinics located in Singapore?

Basel Medical Group Ltd operates clinics at Suntec City Mall, Macpherson Road, Toa Payoh, Margaret Drive, Tampines, Gateway East and Gleneagles Medical Centre in Singapore.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/10/2026 - 06:30 AM Accepted by SEC EDGAR 07/10/2026 - 06:30 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-42527

Basel Medical Group Ltd

6 Napier Road,

Unit #02-10/11 Gleneagles Medical Centre

Singapore 258499

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Exhibit Index

Exhibit No.		Description
99.1		Press Release – BMGL Regains Compliance With Nasdaq Minimum Bid Price Requirement

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Basel Medical Group Ltd
	By:	/s/ Darren Yen Feng Chhoa
	Name:	Dr. Darren Yen Feng Chhoa
	Title:	Chief Executive Officer
Date: July 10, 2026

Exhibit 99.1

BMGL Regains Compliance With Nasdaq Minimum Bid Price Requirement

Singapore, July 10, 2026 (GLOBE NEWSWIRE) — Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today announced that it has received notification from Nasdaq that the Company has regained compliance with the Nasdaq minimum bid price rule. On January 22, 2026, Nasdaq notified the Company that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. Since then, Nasdaq has determined that for the last 10 consecutive business days, from June 23, 2026 to July 7, 2026, the closing bid price of the Company’s ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2).

About Basel Medical Group Ltd

Basel Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine, orthopedic procedures and surgery, as well as neurosurgical treatments, executive health screening services, occupational medicine, rehabilitation, mental and women’s health and general medical practices. Our operations are based in Singapore, with our clinics being located at Suntec City Mall, Macpherson Road, Toa Payoh, Margaret Drive, Tampines, Gateway East and Gleneagles Medical Centre. Over the last 20 years, our group has forged strong and lasting relationships with a wide corporation clientele, particularly those in the construction, marine and oil & gas industries, which underpin our robust business model. As an medical service provider in Singapore with a track record of over 20 years, we are well-positioned to ride the wave of growth opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations, rising income levels, increasing private insurance coverage, increasing expenditure on healthcare, growing sports participation rate and Singapore’s position as a premium destination for healthcare services in Asia. Our management and medical practitioner team comprises a roster of orthopedic and neurosurgery specialists, general practitioners, corporate finance and healthcare partnership specialists. Basel Medical Group Ltd serves as the holding company of our group and we conduct our operations through our operating subsidiaries based in Singapore. For more information, please visit the Company’s website: www.baselmedical.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, which involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

Media Contact:

Basel Medical Group Ltd

+65 6291 9188

contact@baselmedical.com

www.baselmedical.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 9.3 KB